{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:44Z","timestamp":1787009444927,"version":"build-2736575974"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T00:00:00Z","timestamp":1723852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Pfizer and Valneva"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vaccine candidate VLA15 is designed to protect against the dominant Borrelia genospecies-causing Lyme disease in North America and Europe. Active immunization with VLA15 has protected in the mouse model of tick challenge. VLA15 is currently under evaluation in clinical studies for the prevention of Lyme borreliosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Mice were passively administered sera from clinical trial participants vaccinated with VLA15, or normal human serum from unvaccinated individuals as control. Posttransfer serum anti-outer surface protein A (OspA) immunoglobulin G titers were assessed by enzyme-linked immunosorbent assay. Following passive transfer, mice were challenged with Ixodes ticks colonized with Borrelia burgdorferi (OspA serotype 1) or Borrelia afzelii (OspA serotype 2) and infection was determined by serology for VlsE C6 or by polymerase chain reaction and culture to assess the presence of Borrelia bacteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Passive transfer of immune sera prevented transmission of Borrelia from the tick vector and protected mice against challenge. Posttransfer protective threshold immunoglobulin G antibody titers were observed in this animal model of 131\u2005U\/mL for B burgdorferi (OspA serotype 1) and 352\u2005U\/mL for B afzelii (serotype 2).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Passive transfer of sera from trial participants immunized with VLA15 protected mice from borreliosis in a tick challenge model. This indicates that VLA15 induces functional immune responses in people that can be linked to efficacy in a stringent preclinical model.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofae467","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T19:25:08Z","timestamp":1723749908000},"source":"Crossref","is-referenced-by-count":12,"title":["Preclinical Evidence for the Protective Capacity of Antibodies Induced by Lyme Vaccine Candidate VLA15 in People"],"prefix":"10.1093","volume":"11","author":[{"given":"Urban","family":"Lundberg","sequence":"first","affiliation":[{"name":"Valneva Austria GmbH , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Hochreiter","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yekaterina","family":"Timofoyeva","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc. , Pearl River, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isis","family":"Kanevsky","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc. , Pearl River, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meinke","sequence":"additional","affiliation":[{"name":"Valneva Austria GmbH , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annaliesa S","family":"Anderson","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc. , Pearl River, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Simon","sequence":"additional","affiliation":[{"name":"Vaccine Research and Development, Pfizer Inc. , Pearl River, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,17]]},"reference":[{"key":"2024092714531967700_ofae467-B1","doi-asserted-by":"crossref","first-page":"16090","DOI":"10.1038\/nrdp.2016.90","article-title":"Lyme borreliosis","volume":"2","author":"Steere","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2024092714531967700_ofae467-B2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41579-020-0400-5","article-title":"Interactions between Borrelia burgdorferi and ticks","volume":"18","author":"Kurokawa","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"2024092714531967700_ofae467-B3","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/acs.bioconjchem.9b00167","article-title":"Antigen engineering approaches for Lyme disease vaccines","volume":"30","author":"Federizon","year":"2019","journal-title":"Bioconjug Chem"},{"key":"2024092714531967700_ofae467-B4","doi-asserted-by":"crossref","first-page":"e0184357","DOI":"10.1371\/journal.pone.0184357","article-title":"The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes","volume":"12","author":"Comstedt","year":"2017","journal-title":"PLoS One"},{"key":"2024092714531967700_ofae467-B5","doi-asserted-by":"crossref","first-page":"5982","DOI":"10.1016\/j.vaccine.2015.07.095","article-title":"Characterization and optimization of a novel vaccine for protection against Lyme borreliosis","volume":"33","author":"Comstedt","year":"2015","journal-title":"Vaccine"},{"key":"2024092714531967700_ofae467-B6","doi-asserted-by":"crossref","first-page":"e113294","DOI":"10.1371\/journal.pone.0113294","article-title":"Design and development of a novel vaccine for protection against Lyme borreliosis","volume":"9","author":"Comstedt","year":"2014","journal-title":"PLoS One"},{"key":"2024092714531967700_ofae467-B7","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S1473-3099(23)00210-4","article-title":"Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults","volume":"23","author":"Bezay","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2024092714531967700_ofae467-B8","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1128\/IAI.73.3.1644-1647.2005","article-title":"Interactions of OspA monoclonal antibody C3.78 with Borrelia burgdorferi within ticks","volume":"73","author":"Gipson","year":"2005","journal-title":"Infect Immun"},{"key":"2024092714531967700_ofae467-B9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM199807233390401","article-title":"Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group","volume":"339","author":"Steere","year":"1998","journal-title":"N Engl J Med"},{"key":"2024092714531967700_ofae467-B10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJM199807233390402","article-title":"A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium","volume":"339","author":"Sigal","year":"1998","journal-title":"N Engl J Med"},{"key":"2024092714531967700_ofae467-B11","doi-asserted-by":"crossref","first-page":"e0030622","DOI":"10.1128\/iai.00306-22","article-title":"Agglutination of Borreliella burgdorferi by transmission-blocking OspA monoclonal antibodies and monovalent fab fragments","volume":"90","author":"Frye","year":"2022","journal-title":"Infect Immun"},{"key":"2024092714531967700_ofae467-B12","doi-asserted-by":"crossref","first-page":"e79022","DOI":"10.1371\/journal.pone.0079022","article-title":"Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model","volume":"8","author":"Schwendinger","year":"2013","journal-title":"PLoS One"},{"key":"2024092714531967700_ofae467-B13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3390\/microorganisms12010185","article-title":"Microbiologic findings in a cohort of patients with erythema migrans","volume":"12","author":"Ruzic-Sabljic","year":"2024","journal-title":"Microorganisms"},{"key":"2024092714531967700_ofae467-B14","doi-asserted-by":"crossref","first-page":"e00609-17","DOI":"10.1128\/AEM.00609-17","article-title":"Europe-wide meta-analysis of Borrelia burgdorferi sensu lato prevalence in questing Ixodes ricinus ticks","volume":"83","author":"Strnad","year":"2017","journal-title":"Appl Environ Microbiol"},{"key":"2024092714531967700_ofae467-B15","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1086\/514779","article-title":"Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine","volume":"28","author":"Van Hoecke","year":"1999","journal-title":"Clin Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae467\/58840553\/ofae467.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/9\/ofae467\/59361401\/ofae467.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/9\/ofae467\/59361401\/ofae467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T10:53:32Z","timestamp":1727434412000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae467\/7734862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,17]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,8,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae467","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,17]]},"article-number":"ofae467"}}